TrialWatch: BI & Lilly EMPA-REG OUTCOME Trial Results

As reported recently in Endocrinology Advisor, Boehringer Ingelheim and Lilly’s EMPA-REG OUTCOME trial was set up to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk. The results, recently published in Diabetes Care, evidence that Empagliflozin may reduce cardiovascular morality in type 2 diabetes with left ventricular hypertrophy. The investigators recommended that future studies evaluate the impact empagliflozin has on less stringent definitions of left ventricular hypertrophy and whether the treatment can cause remission in left ventricular mass.

Researchers concluded that for patients with T2D with or without left ventricular hypertrophy, “empagliflozin consistently reduced the risks [for] cardiovascular and all-cause mortality.” Follow the link for the entire story.